Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Medical Genetics · Familial Hypobetalipoproteinemia Type 1

Understanding Your FHBL1 Diagnosis

At a Glance

FHBL1 is an inherited condition in which changes in the APOB gene lead to very low LDL cholesterol. Diagnosis uses repeat lipid tests, ApoB measurement, family evaluation, and genetic testing while ruling out other causes; follow-up focuses on liver health and fat-soluble vitamins.

Receiving a diagnosis of Familial Hypobetalipoproteinemia Type 1 (FHBL1) can be a confusing experience. In a world where most people are told their cholesterol is too high, being told yours is “too low” feels like a contradiction [1]. You may have even been told you are “lucky” to have such low numbers. However, FHBL1 is a specific genetic condition that requires medical attention because, in this context, extremely low cholesterol is not a lifestyle achievement—it is a sign that your body’s transport system for fats is not working correctly [2][3].

The Role of the APOB Gene

At the center of FHBL1 is a gene called APOB. This gene provides instructions for making Apolipoprotein B (ApoB), a protein that acts like a cargo ship for fats (lipids) and cholesterol in your bloodstream [4]. These “ships” are essential for moving energy and nutrients from your liver and intestines to the rest of your body [5].

In FHBL1, variants in the APOB gene cause these ships to be “truncated” (shortened) or not produced in enough quantity [4]. Because the ships are broken or missing, the fats they are supposed to carry can get stuck in the liver or may not be absorbed properly from your diet [2][3].

Understanding Codominant Inheritance

FHBL1 is inherited in a codominant manner, which means the severity of the condition depends on whether you inherited one or two pathogenic copies of the gene:

  • Heterozygous (One Copy): Most people with FHBL1 have one mutated gene and one normal gene. They often have very low LDL cholesterol (often below 50 mg/dL) but may have no outward symptoms [5][3]. The main risk for this group is hepatic steatosis (fatty liver), because the liver cannot export fat effectively [2][1].
  • Biallelic (Two Copies): This is a much rarer and more severe form where both copies of the gene are mutated. This can lead to extremely low LDL (often below 20 mg/dL) and symptoms like severe difficulty absorbing dietary fats and vitamins [5][6].

Diagnostic Clues: When “Low” is Too Low

Doctors typically suspect FHBL1 when your cholesterol levels fall below the 5th percentile for your age and sex [7][8]. While exact numbers vary, a common clinical “trigger” for further investigation is an LDL-C level below 50 mg/dL [9][3]. However, these are screening clues, not absolute diagnostic rules.

The diagnosis is usually confirmed through:

  1. Repeat Lipid Panels: To ensure the low levels are persistent and not a one-time fluke [7].
  2. ApoB Measurement: Checking the actual amount of the transport protein in your blood [3].
  3. Family Testing: Checking the cholesterol levels of your parents, siblings, or children to see if the pattern is shared [5][10].
  4. Genetic Testing: Using a blood test to look for specific variants in the APOB gene [11][4].

Why Evaluation Matters

While an incidental finding of FHBL1 is generally not a medical emergency, it does require a thorough evaluation to rule out other causes and monitor for potential complications. Note: Patients should not start a low-fat diet, take high-dose vitamins, or stop lipid-lowering medication based on a single low result without specialist guidance.

Ruling Out Secondary Causes

Before confirming FHBL1, your doctor must ensure your low cholesterol isn’t caused by something else (secondary causes), such as:

  • Uncontrolled hyperthyroidism [12].
  • Chronic infections or severe illness (including recent COVID-19) [13][14].
  • Malnutrition or severe malabsorption issues [12].
  • Advanced liver disease or certain cancers [15][12].
  • Medications like high-dose statins or newer cholesterol-lowering drugs [16].

Monitoring for Complications

The most common concern in FHBL1 is the health of your liver. Because fats cannot be shipped out, they can accumulate, leading to hepatic steatosis (fatty liver) [2][1]. In some cases, this can lead to inflammation or elevated liver enzymes (AST and ALT) [3][17].

Additionally, because these “cargo ships” also carry fat-soluble vitamins (A, D, E, and K), your doctor may want to monitor your vitamin levels [3][18]. While severe deficiencies are rare in people with only one mutated gene, they are possible in severe forms and can affect vision, bone health, and nerve function if left untreated [5][6].

Living with the Diagnosis

For most people, FHBL1 is a condition that is managed through individualized monitoring rather than intensive treatment. Knowing about the diagnosis allows you and your care team to keep an eye on your liver health and ensure you are getting the nutrients your body needs [3][19]. While the world focuses on lowering cholesterol, your goal is to ensure your unique lipid profile is handled with the specialized care it deserves.

Common questions in this guide

What is familial hypobetalipoproteinemia type 1 (FHBL1)?
FHBL1 is an inherited condition caused by changes in the APOB gene, which makes apolipoprotein B, a protein that carries fats and cholesterol in the blood. The result is unusually low LDL cholesterol; people with one altered copy may have few symptoms, while changes in both copies can cause more severe fat and vitamin absorption problems.
How do doctors confirm an FHBL1 diagnosis?
Doctors usually repeat the lipid panel, measure ApoB, review cholesterol patterns in close relatives, and use genetic testing to look for an APOB variant. They also check for other explanations for very low cholesterol before confirming FHBL1.
Can very low LDL cholesterol have causes other than FHBL1?
Yes. An overactive thyroid, a recent infection or severe illness, malnutrition or malabsorption, advanced liver disease, some cancers, and cholesterol-lowering medicines can also lower cholesterol, so these possibilities need evaluation.
What health problems should be monitored with FHBL1?
The main concern is hepatic steatosis, also called fatty liver, which can be associated with elevated AST or ALT liver enzymes. In more severe forms, poor absorption of fat-soluble vitamins A, D, E, and K can affect vision, bones, or nerves.
Should I change my diet or take vitamins if my cholesterol is very low?
Do not start a low-fat diet or high-dose vitamins, or stop a cholesterol medicine, based on one low result without medical guidance. A clinician can determine whether FHBL1 or another condition is present and recommend monitoring or treatment that fits your results.
Do family members need testing for FHBL1?
Because FHBL1 is inherited and its severity can depend on whether a person has one or two altered APOB copies, parents, siblings, and children may also be affected. A clinician can decide whether relatives should have lipid testing, genetic testing, or both.

Get notified when new evidence is published on Familial hypobetalipoproteinemia 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia.

    Di Costanzo A, Di Leo E, Noto D, et al.

    Journal of clinical lipidology 2017; (11(5)):1234-1242 doi:10.1016/j.jacl.2017.06.013.

    PMID: 28733173
  2. 2

    Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia.

    Rimbert A, Vanhoye X, Coulibaly D, et al.

    Arteriosclerosis, thrombosis, and vascular biology 2021; (41(1)):e63-e71 doi:10.1161/ATVBAHA.120.315491.

    PMID: 33207932
  3. 3

    Clinical and biochemical spectrum of APOB-related hypobetalipoproteinemia: Insights from a retrospective cohort study.

    Sürücü Kara İ, Köse E, Mutlu H, et al.

    Journal of clinical lipidology 2025; (19(3)):605-616 doi:10.1016/j.jacl.2025.02.003.

    PMID: 40155282
  4. 4

    Molecular analysis of APOB, SAR1B, ANGPTL3, and MTTP in patients with primary hypocholesterolemia in a clinical laboratory setting: Evidence supporting polygenicity in mutation-negative patients.

    Blanco-Vaca F, Martin-Campos JM, Beteta-Vicente Á, et al.

    Atherosclerosis 2019; (283()):52-60 doi:10.1016/j.atherosclerosis.2019.01.036.

    PMID: 30782561
  5. 5

    Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1.

    Wakabayashi T, Takahashi M, Okazaki H, et al.

    Journal of atherosclerosis and thrombosis 2024; (31(7)):1005-1023 doi:10.5551/jat.RV22018.

    PMID: 38710625
  6. 6

    Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia.

    Burnett JR, Hooper AJ

    Free radical biology & medicine 2015; (88(Pt A)):59-62.

    PMID: 26086616
  7. 7

    A case of hypocholesterolemia under study.

    Camacho A, Ariza MJ, Amigó N, et al.

    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2023; (35(5)):244-247 doi:10.1016/j.arteri.2023.05.003.

    PMID: 37302939
  8. 8

    APOB CRISPR-Cas9 Engineering in Hypobetalipoproteinemia: A Promising Tool for Functional Studies of Novel Variants.

    Vanhoye X, Janin A, Caillaud A, et al.

    International journal of molecular sciences 2022; (23(8)) doi:10.3390/ijms23084281.

    PMID: 35457099
  9. 9

    Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?

    Mouzaki M, Shah A, Arce-Clachar AC, et al.

    Journal of clinical lipidology 2019; (13(3)):425-431 doi:10.1016/j.jacl.2019.02.002.

    PMID: 30879942
  10. 10

    Comparison of two polygenic risk scores to identify non-monogenic primary hypocholesterolemias in a large cohort of Italian hypocholesterolemic subjects.

    Cefalù AB, Spina R, Noto D, et al.

    Journal of clinical lipidology 2022; (16(4)):530-537 doi:10.1016/j.jacl.2022.04.009.

    PMID: 35589500
  11. 11

    Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.

    Rimbert A, Pichelin M, Lecointe S, et al.

    Atherosclerosis 2016; (250()):52-6.

    PMID: 27179706
  12. 12

    Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

    Privitera G, Spadaro L, Marchisello S, et al.

    Digestive diseases and sciences 2018; (63(1)):16-26 doi:10.1007/s10620-017-4862-x.

    PMID: 29177578
  13. 13

    Hypolipidemia is associated with the severity of COVID-19.

    Wei X, Zeng W, Su J, et al.

    Journal of clinical lipidology 2020; (14(3)):297-304 doi:10.1016/j.jacl.2020.04.008.

    PMID: 32430154
  14. 14

    Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19.

    Aparisi Á, Iglesias-Echeverría C, Ybarra-Falcón C, et al.

    Nutrition, metabolism, and cardiovascular diseases : NMCD 2021; (31(9)):2619-2627 doi:10.1016/j.numecd.2021.06.016.

    PMID: 34353699
  15. 15

    The evaluation of serum lipid profile in chronic Hepatitis B patients at a Tertiary Care Centre in Western India: A cross-sectional study.

    Meena DS, Kumar D, Garg MK, et al.

    Annals of African medicine 2022; (21(4)):316-321 doi:10.4103/aam.aam_35_21.

    PMID: 36412329
  16. 16

    PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.

    Gunta SP, O'Keefe JH, O'Keefe EL, Lavie CJ

    Progress in cardiovascular diseases 2023; (79()):12-18 doi:10.1016/j.pcad.2023.02.007.

    PMID: 36871887
  17. 17

    Case report: Unusual coexistence between familial hypercholesterolemia and familial hypobetalipoproteinemia.

    Sasaki K, Tada H, Kawashiri MA, Ito T

    Frontiers in cardiovascular medicine 2022; (9()):942772 doi:10.3389/fcvm.2022.942772.

    PMID: 36003908
  18. 18

    Vitamin K1 as a screening marker to facilitate the genetic diagnosis of class I familial hypobetalipoproteinemia: A prospective cohort study with a systematic review analysis.

    Tanaka M, Okazaki S, Takahashi M, et al.

    Journal of clinical lipidology 2026; (20(8)):1656-1666 doi:10.1016/j.jacl.2026.06.013.

    PMID: 42399142
  19. 19

    Lipids Responsible for Intestinal or Hepatic Disorder: When to Suspect a Familial Intestinal Hypocholesterolemia?

    Sissaoui S, Cochet M, Poinsot P, et al.

    Journal of pediatric gastroenterology and nutrition 2021; (73(1)):4-8 doi:10.1097/MPG.0000000000003145.

    PMID: 33853111

This page is for informational purposes only and does not constitute medical advice. Discuss your very low cholesterol, genetic testing, liver tests, and vitamin monitoring with your healthcare professional before changing your diet, supplements, or medicines.

Guide contents Familial hypobetalipoproteinemia 1
Research & Literature
02 Two Genetic Paths